2024 FUTURES Responding to AAV Based Treatment Challenges
A moderated panel discussion focusing on the potential challenges and complications of AAV therapy and the clinical strategies to make dosing AAV more successful.
![](https://cureduchenne.org/wp-content/uploads/2020/12/Mike-Kelly.jpg)
![](https://cureduchenne.org/wp-content/uploads/2022/06/barry.png)
Barry Byrne, MD, PhD
Professor and Associate Chair
University of Florida, Department of Pediatrics
![](https://cureduchenne.org/wp-content/uploads/2023/08/Carsten-Bonnemann-MD.webp)
Carsten Bönnemann, MD
Chief, Neuromuscular and Neurogenetic Disorders of Childhood Section National Institute of Neurological Disorders and Stroke/NIH
![](https://cureduchenne.org/wp-content/uploads/2023/08/Kevin-Flanigan-MD.webp)
Kevin Flanigan, MD
Director, Center for Gene Therapy Nationwide Children's Hospital
![](https://cureduchenne.org/wp-content/uploads/2024/06/Robyn-van-Poelgeest.jpg)
![](https://cureduchenne.org/wp-content/uploads/2024/06/sharif.jpg)
Sharif Tabebordbar, PhD
Co-Founder and Chief Scientific Officer
Kate Therapeutics
Video
![](https://cureduchenne.org/wp-content/uploads/2023/08/futures-hero-mob-all.png)